CGON Stock Summary and Trading Ideas (CG Oncology | NASDAQ:CGON)

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology trades on the NASDAQ stock market under the symbol CGON.

As of September 3, 2026, CGON stock price declined to $74.33 with 330,765 million shares trading.

CGON has a beta of 0.75, meaning it tends to be less sensitive to market movements. CGON has a correlation of 0.03 to the broad based SPY ETF.

CGON has a market cap of $6.59 billion. This is considered a Mid Cap stock.

Last quarter CG Oncology reported $1 million in Revenue and -$.90 earnings per share. This beat revenue expectation by $325,208 and missed earnings estimates by -$.25.

The top ETF exchange traded funds that CGON belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.

CGON has outperformed the market in the last year with a return of +159.3%, while the SPY ETF gained +21.3%. In the last 3 month period, CGON beat the market returning +36.6%, while SPY returned +2.8%. However, in the most recent 2 weeks CGON has underperformed the stock market by returning -4.2%, while SPY returned +1.4%.

CGON support price is $72.58 and resistance is $76.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGON shares will trade within this expected range on the day.